专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2024272A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME 审中-公开
标题翻译： AMIDDERIVATE ALS IONENKANALLIGANDEN SOWIE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND VERWENDUNGSVERFAHRENDAFÜR
公开(公告)号：EP2024272A2
公开(公告)日：2009-02-18
申请号：EP07794735.6
申请日：2007-05-10
申请人： Renovis, Inc. , Pfizer, Inc.
发明人： SHISHIDO, Yuji , NAKAO, Kazunari , NAGAYAMA, Satoshi , TANAKA, Hirotaka , DUNCTON, Matthew, Alexander James , COX, Matthew , KINCAID, John , SAHASRABUDHE, Kiran , ESTIARTE-MARTINEZ, Maria de Los Angeles
IPC分类号： B82B1/00 , A61K31/497
CPC分类号： C07D215/48 , C07C311/08 , C07C2601/02 , C07D205/04 , C07D215/54 , C07D217/26 , C07D231/12 , C07D239/94 , C07D241/44 , C07D295/155 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/12 , C07D471/04 , C07D498/04 , C07D498/12
摘要： Compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.
摘要翻译：公开了具有由下式表示的式的化合物：式（I）。化合物可以制备为药物组合物，并且可以用于预防和治疗包括人在内的哺乳动物中的各种病症，包括作为非限制性实例，疼痛，炎症，创伤性损伤等。

2. 发明公开

EP0787127A1 5-LIPOXYGENASE INHIBITORS 失效
标题翻译： 5脂氧合酶抑制剂
公开(公告)号：EP0787127A1
公开(公告)日：1997-08-06
申请号：EP95918121.0
申请日：1995-05-29
申请人： PFIZER INC.
发明人： STEVENS, Rodney, W. , MANO, Takashi , NAKAO, Kazunari , OKUMURA, Yoshiyuki
IPC分类号： A61K31 , A61P9 , A61P29 , A61P37 , A61P43 , C07D233 , C07D309 , C07D405 , C07D521
CPC分类号： C07D231/12 , C07D233/56 , C07D249/08 , C07D309/08
摘要： Novel compounds having the ability to inhibit 5-lipoxygenase enzyme and having formula (I) and the pharmaceutically acceptable salts thereof, wherein Ar1 is a heterocyclic moiety which is selected from imidazolyl, pyrrolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, indolyl, indazolyl and benzimidazolyl, which is bonded to X1 through a ring nitrogen atom, and which may be optionally substituted with one or two substituents selected from halo, hydroxy, cyano, amino, C¿1-4? alkyl and the like; X?1¿ is a direct bond or C¿1-4? alkylene; Ar?2¿ is phenylene optionally substituted with halo, hydroxy, cyano, amino and the like; X2 is -A-X- or -X-A- wherein A is a direct bond or C¿1-4? alkylene and X is oxy, thio, sulfinyl or sulfonyl; Ar?3¿ is phenylene, pyridylene, thienylene, furylene, oxazolylene or thiazolylene optionally substituted with one or two substituents selected from halo, hydroxy, cyano, amino, C¿1-4? alkyl and the like; R?1 and R2¿ are each C¿1-4? alkyl, or together they form a group of formula -D?1-Z-D2¿- which together with the carbon atom to which it is attached defines a ring having 3 to 8 atoms, wherein D?1 and D2¿ are C¿1-4? alkylene and Z is a direct bond or oxy, thio, sulfinyl, sulfonyl, or vinylene, and D?1 and D2¿ may be substituted by C¿1-3? alkyl; and Y is CONR?3R4¿, CN, C(R?3)=N-OR4, COOR3, COR3¿ or CSNR3R4, wherein R?3 and R4¿ are each H or C¿1-4? alkyl. These compounds are useful in the treatment or alleviation of inflammatory diseases, allergy and cardiovascular diseases in mammals and as the active ingredient in pharmaceutical compositions for treating such conditions.

3. 发明授权

EP1858865B1 SUBSTITUTED N-SULFONYLAMINOPHENYLETHYL-2-PHENOXY ACETAMIDE COMPOUNDS 有权
标题翻译：取代的N-磺酰基氨基苯乙烯基乙基-2-苯氧基乙酰胺化合物
公开(公告)号：EP1858865B1
公开(公告)日：2009-09-16
申请号：EP06710536.1
申请日：2006-02-24
申请人： PFIZER INC.
发明人： HANAZAWA, Takeshi Pfizer Global Res. & Dev. Nagoya , HIRANO, Misato Pfizer Global Res. & Dev. Nagoya , INOUE, Tadashi Pfizer Global Res. & Dev. Nagoya , NAHAYAMA, Satoshi Pfizer Global Res. & Dev. Nagoya , NAKAO, Kazunari , SHISHIDO, Yuji Pfizer Global Res. & Dev. Nagoya , TANAKA, Hirotaka Pfizer Global Res. & Dev. Nagoya
IPC分类号： C07D295/08 , C07D311/58 , C07C311/08 , A61K31/4453 , A61K31/353 , A61K31/18 , A61P25/00
CPC分类号： C07C311/08
摘要： This invention provides a compound of the formula (I), wherein R 1 represents (C 1 -C 6 )alkyl; R 2 represents a hydrogen atom, a halogen atom, a hydroxy group, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl or halo(C 1 -C 6 )alkyl; R 3 represents a halogen atom, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyll, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkylsulfinyl, (C 1 C 6 )alkyllsulfonyl, [(C 1 -C 6 )alkyl]NH-, or [(C 1 -C 6 ) alkyl] 2 N-; R 4 represents a halogen atom, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, [(C 1 -C 6 )alkyl]NH-, or [(C 1 -C 6 )alkyl] 2 N-; R 5 represents a halogen atom, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyll, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkylsulfinyl, (C 1 -C 6 )alkyIsulfonyl, [(C 1 -C 6 )alkyl]NH-, [(C 1 -C 6 ) alkyl] 2 N-, H 2 N-(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkyl-NH-(C 1 -C 6 )alkoxy, [(C 1 -C 6 )alkyl] 2 N(C 1 -C 6 )alkoxy, H 2 N-(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl-NH-(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, or [(C 1 -C 6 )alkyl] 2 N(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl; and *indicates a chiral centre; or a pharmaceutically acceptable salt or solvate thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.
摘要翻译：本发明提供了式（I）的化合物，其中R 1表示（C 1 -C 6）烷基; （C1-C6）烷基，（C1-C6）烷氧基，羟基（C1-C6）烷基，（C1-C6）烷氧基 - （C1-C6）烷基或卤代（C1-C6）烷基; （C 1 -C 6）烷氧基，羟基（C 1 -C 6）烷氧基，（C 1 -C 6）烷氧基 - （C 1 -C 6）烷基，（C 1 -C 6）烷氧基 - （（C 1 -C 6）烷硫基，（C 1 -C 6）烷基亚磺酰基，（C 1 -C 6）烷基磺酰基，[（C 1 -C 6）烷基] NH-或[（C 1 -C 6））烷基] 2 N - ; （C 1 -C 6）烷基，（C 1 -C 6）烷氧基，羟基（C 1 -C 6）烷氧基，（C 1 -C 6）烷氧基 - （C 1 -C 6）烷基，（C 1 -C 6）烷氧基 - （C 1 -C 6）烷氧基，[（C 1 -C 6）烷基] NH-或[（C 1 -C 6）烷基] 2 N- （C 1 -C 6）烷氧基，羟基（C 1 -C 6）烷氧基，（C 1 -C 6）烷氧基 - （C 1 -C 6）烷基，（C 1 -C 6）烷氧基 - （（C 1 -C 6）烷硫基，（C 1 -C 6）烷基亚磺酰基，（C 1 -C 6）烷基磺酰基，[（C 1 -C 6）烷基] NH-， C6）烷基] 2N-，H2N-（C1-C6）烷氧基，（C1-C6）烷基-NH-（C1-C6）烷氧基，[（C1-C6）烷基] 2N （C 1 -C 6）烷氧基 - （C 1 -C 6）烷基，（C 1 -C 6）烷基-NH-（C 1 -C 6）烷氧基 - （C 1 -C 6）烷基， C6）烷氧基 - （C1-C6）烷基; *表示手性中心; 或其药学上可接受的盐或溶剂合物。这些化合物可用于治疗由VR1受体的过度激活引起的疾病状态，例如哺乳动物的疼痛等。本发明还提供了包含上述化合物的药物组合物。

4. 发明公开

EP0636119A1 PHENYL SUBSTITUTED CYCLOALKYL HYDROXYUREA DERIVATIVES WHICH INHIBIT LIPOXYGENASE 失效
标题翻译：环丙基羟基 - 羟基丙烯酰氧基丙烯酸酯（LIPOXYGENASE-HEMMER）。
公开(公告)号：EP0636119A1
公开(公告)日：1995-02-01
申请号：EP93905957.0
申请日：1993-02-18
申请人： PFIZER INC.
发明人： NAKAO, Kazunari , KAWAI, Akiyoshi , STEVENS, Rodney W.
IPC分类号： A61K31 , A61P9 , A61P29 , A61P37 , A61P43 , C07C275 , C07C323
CPC分类号： C07C275/64 , C07C323/47 , C07C2601/04 , C07C2601/08
摘要： Certain novel phenylsubstituted cycloalkylurea compounds having the ability to inhibit the enzyme 5-lipoxygenase and having formula (I); wherein A is C1-C4 alkylene or C2-C6 alkenylene; each B is independently halogen, C1-C4 alkyl, C2-C8 alkoxyalkyl or halosubstituted C1-C4 alkyl; X is methylene or ethylene; M is hydrogen or a pharmaceutically acceptable cation; A r is phenyl or mono-, di- or tri-substituted phenyl wherein the substituents are each independently selected from halogen, C1-C4 alkyl, C1-C4 alkoxy, halosubstituted C1-C4 alkyl, (C1-C4 alkyl)phenoxy, (C1-C4 alkoxy)phenoxy, halosubstituted phenoxy, halosubstituted (C1-C4 alkyl)phenoxy, phenylthio, (C1-C4 alkyl)phenylthio, (C1-C4 alkoxy)phenylthio, halosubstituted phenylthio and halosubstituted (C1-C4 alkyl)phenylthio; A, B and Ar may be attached at any available position on the ring; m is 0 or 1; and n is 0, 1 or 2. These compounds are useful in the treatment or alleviation of inflammatory diseases, allergic conditions and cardiovascular diseases in mammals and as the active ingredient in pharmaceutical compositions for treating such conditions.
摘要翻译：某些新型苯基取代的环烷基脲化合物，其具有抑制酶5-脂氧合酶并具有式（I）的能力; 其中A为C1-C4亚烷基或C2-C6亚链烯基; 每个B独立地是卤素，C 1 -C 4烷基，C 2 -C 8烷氧基烷基或卤素取代的C 1 -C 4烷基; X是亚甲基或亚乙基; M是氢或药学上可接受的阳离子; A是苯基或单 - ，二 - 或三 - 取代的苯基，其中取代基各自独立地选自卤素，C 1 -C 4烷基，C 1 -C 4烷氧基，卤代C 1 -C 4烷基，（C 1 -C 4烷基）苯氧基，（ C 1 -C 4烷氧基）苯氧基，卤代取代的苯氧基，卤代（C 1 -C 4烷基）苯氧基，苯硫基，（C 1 -C 4烷基）苯硫基，（C 1 -C 4烷氧基）苯硫基，卤代取代的苯硫基和卤素取代的（C 1 -C 4烷基） A，B和Ar可以在环上的任何可用位置附着; m为0或1; 并且n为0,1或2.这些化合物可用于治疗或缓解哺乳动物的炎性疾病，过敏性疾病和心血管疾病，以及作为用于治疗这些病症的药物组合物中的活性成分。

5. 发明授权

EP1861359B1 N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN 有权
标题翻译：疼痛SUITABLE N-（N- sulfonylaminomethyl）环丙烷羧酸酰胺衍生物的治疗
公开(公告)号：EP1861359B1
公开(公告)日：2012-11-14
申请号：EP06710543.7
申请日：2006-03-07
申请人： Pfizer Inc.
发明人： HANAZAWA, Takeshi , HIRANO, Misato , INOUE, Tadashi , NAGAYAMA, Satoshi , NAKAO, Kazunari , SHISHIDO, Yuji , TANAKA, Hirotaka
IPC分类号： C07C311/08 , C07C317/44 , C07C323/62 , C07D213/56 , C07D213/74 , C07D213/76 , A61P29/00 , A61K31/145 , A61K31/44
CPC分类号： C07C61/28 , C07C61/40 , C07C311/08 , C07C317/44 , C07C323/62 , C07C2601/02 , C07D213/26 , C07D213/56 , C07D213/74 , C07D213/76

6. 发明公开

EP2044018A1 SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS 审中-公开
标题翻译：取代的N-二环己基双环羧酰胺化合物
公开(公告)号：EP2044018A1
公开(公告)日：2009-04-08
申请号：EP07734995.9
申请日：2007-07-02
申请人： Pfizer Japan, Inc. , Pfizer, Inc.
发明人： KAWASHIMA, Tadashi , NAGAYAMA, Satoshi , NAKAO, Kazunari , TANAKA, Hirotaka
IPC分类号： C07D209/34 , C07D215/06 , C07D231/56 , C07D249/18 , C07D403/12 , A61K31/395 , A61P25/00
CPC分类号： C07D209/34 , C07D215/06 , C07D231/56 , C07D249/18 , C07D403/12
摘要： This invention provides a compound of the formula (I): And their use for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.
摘要翻译：本发明提供了式（I）化合物：及其用于治疗由哺乳动物中VR1受体过度激活引起的疾病如疼痛等的用途。本发明还提供了包含上述化合物的药物组合物。

7. 发明授权

EP0787127B1 5-LIPOXYGENASE INHIBITORS 失效
标题翻译： 5脂氧合酶抑制剂
公开(公告)号：EP0787127B1
公开(公告)日：2001-01-03
申请号：EP95918121.5
申请日：1995-05-29
申请人： PFIZER INC.
发明人： STEVENS, Rodney, W. , MANO, Takashi , NAKAO, Kazunari , OKUMURA, Yoshiyuki
IPC分类号： C07D233/60 , C07D405/12 , A61K31/415
CPC分类号： C07D231/12 , C07D233/56 , C07D249/08 , C07D309/08
摘要： Novel compounds having the ability to inhibit 5-lipoxygenase enzyme and having formula (I) and the pharmaceutically acceptable salts thereof, wherein Ar1 is a heterocyclic moiety which is selected from imidazolyl, pyrrolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, indolyl, indazolyl and benzimidazolyl, which is bonded to X1 through a ring nitrogen atom, and which may be optionally substituted with one or two substituents selected from halo, hydroxy, cyano, amino, C¿1-4? alkyl and the like; X?1¿ is a direct bond or C¿1-4? alkylene; Ar?2¿ is phenylene optionally substituted with halo, hydroxy, cyano, amino and the like; X2 is -A-X- or -X-A- wherein A is a direct bond or C¿1-4? alkylene and X is oxy, thio, sulfinyl or sulfonyl; Ar?3¿ is phenylene, pyridylene, thienylene, furylene, oxazolylene or thiazolylene optionally substituted with one or two substituents selected from halo, hydroxy, cyano, amino, C¿1-4? alkyl and the like; R?1 and R2¿ are each C¿1-4? alkyl, or together they form a group of formula -D?1-Z-D2¿- which together with the carbon atom to which it is attached defines a ring having 3 to 8 atoms, wherein D?1 and D2¿ are C¿1-4? alkylene and Z is a direct bond or oxy, thio, sulfinyl, sulfonyl, or vinylene, and D?1 and D2¿ may be substituted by C¿1-3? alkyl; and Y is CONR?3R4¿, CN, C(R?3)=N-OR4, COOR3, COR3¿ or CSNR3R4, wherein R?3 and R4¿ are each H or C¿1-4? alkyl. These compounds are useful in the treatment or alleviation of inflammatory diseases, allergy and cardiovascular diseases in mammals and as the active ingredient in pharmaceutical compositions for treating such conditions.

8. 发明公开

EP1045833A1 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS 有权
标题翻译： 2,3-取代的吲哚化合物作为COX-2抑制剂
公开(公告)号：EP1045833A1
公开(公告)日：2000-10-25
申请号：EP98959082.3
申请日：1998-12-18
申请人： PFIZER INC.
发明人： NAKAO, Kazunari , STEVENS, Rodney, William , KAWAMURA, Kiyoshi , UCHIDA, Chikara , KOIKE, Hiroki , CARON, Stephane
IPC分类号： C07D209/18 , A61K31/40 , C07D401/06 , C07D403/06 , C07D417/06 , C07D405/06 , C07D409/10 , C07D405/10 , C07D401/10 , C07D417/10 , C07D413/06 , C07D409/06
CPC分类号： C07D401/06 , C07D209/18 , C07D401/10 , C07D403/06 , C07D405/06 , C07D405/10 , C07D409/06 , C07D409/10 , C07D413/06 , C07D417/06 , C07D417/10
摘要： This invention provides a compound of formula (I) or the pharmaceutically acceptable salts thereof wherein Z is OH, C1-6 alkoxy, -NR2R3 or heterocycle; Q is selected from the following: (a) an optionally substituted phenyl, (b) an optionally substituted 6-membered monocyclic aromatic group containing one, two, three or four nitrogen atom(s), (c) an optionally substituted 5-membered monocyclic aromatic group containing one heteroatom selected from O, S and N and optionally containing one, two or three nitrogen atom(s) in addition to said heteroatom, (d) an optionally substituted C¿3-7? cycloalkyl and (e) an optionally substituted benzofuzed heterocycle; R?1¿ is hydrogen, C¿1-4? alkyl or halo; R?2 and R3¿ are independently hydrogen, OH, C¿1-4? alkoxy, C1-4 alkyl or C1-4 alkyl substituted with halo, OH, C1-4 alkoxy or CN; X is independently selected from H, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, OH, C1-4 alkoxy, halo-substituted C1-4 alkoxy, C1-4 alkylthio, NO2, NH2, di-(C1-4 alkyl)amino and CN; and n is 0, 1, 2, 3 and 4. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.

9. 发明授权

EP0636119B1 PHENYL SUBSTITUTED CYCLOALKYL HYDROXYUREA DERIVATIVES WHICH INHIBIT LIPOXYGENASE 失效
标题翻译：环丙基羟基苯甲酸羟基苯甲酸羟丙酯（LIPOXYGENASE-HEMMER）
公开(公告)号：EP0636119B1
公开(公告)日：1997-11-05
申请号：EP93905957.2
申请日：1993-02-18
申请人： PFIZER INC.
发明人： NAKAO, Kazunari , KAWAI, Akiyoshi , STEVENS, Rodney W.
IPC分类号： C07C275/64 , C07C323/47 , A61K31/17
CPC分类号： C07C275/64 , C07C323/47 , C07C2601/04 , C07C2601/08
摘要： Certain novel phenylsubstituted cycloalkylurea compounds having the ability to inhibit the enzyme 5-lipoxygenase and having formula (I); wherein A is C1-C4 alkylene or C2-C6 alkenylene; each B is independently halogen, C1-C4 alkyl, C2-C8 alkoxyalkyl or halosubstituted C1-C4 alkyl; X is methylene or ethylene; M is hydrogen or a pharmaceutically acceptable cation; A r is phenyl or mono-, di- or tri-substituted phenyl wherein the substituents are each independently selected from halogen, C1-C4 alkyl, C1-C4 alkoxy, halosubstituted C1-C4 alkyl, (C1-C4 alkyl)phenoxy, (C1-C4 alkoxy)phenoxy, halosubstituted phenoxy, halosubstituted (C1-C4 alkyl)phenoxy, phenylthio, (C1-C4 alkyl)phenylthio, (C1-C4 alkoxy)phenylthio, halosubstituted phenylthio and halosubstituted (C1-C4 alkyl)phenylthio; A, B and Ar may be attached at any available position on the ring; m is 0 or 1; and n is 0, 1 or 2. These compounds are useful in the treatment or alleviation of inflammatory diseases, allergic conditions and cardiovascular diseases in mammals and as the active ingredient in pharmaceutical compositions for treating such conditions.
摘要翻译：某些新型苯基取代的环烷基脲化合物，其具有抑制酶5-脂氧合酶并具有式（I）的能力; 其中A为C1-C4亚烷基或C2-C6亚链烯基; 每个B独立地是卤素，C 1 -C 4烷基，C 2 -C 8烷氧基烷基或卤素取代的C 1 -C 4烷基; X是亚甲基或亚乙基; M是氢或药学上可接受的阳离子; A是苯基或单 - ，二 - 或三 - 取代的苯基，其中取代基各自独立地选自卤素，C 1 -C 4烷基，C 1 -C 4烷氧基，卤代C 1 -C 4烷基，（C 1 -C 4烷基）苯氧基，（ C 1 -C 4烷氧基）苯氧基，卤代取代的苯氧基，卤代（C 1 -C 4烷基）苯氧基，苯硫基，（C 1 -C 4烷基）苯硫基，（C 1 -C 4烷氧基）苯硫基，卤代取代的苯硫基和卤素取代的（C 1 -C 4烷基） A，B和Ar可以在环上的任何可用位置附着; m为0或1; 并且n为0,1或2.这些化合物可用于治疗或缓解哺乳动物的炎性疾病，过敏性疾病和心血管疾病，以及作为用于治疗这些病症的药物组合物中的活性成分。

10. 发明公开

EP1861359A1 N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN 有权
标题翻译： FüRDIE BEHANDLUNG VON SCHMERZEN GEEIGNETE N-（N-磺酰氨基乙基）环丙基碳二亚胺
公开(公告)号：EP1861359A1
公开(公告)日：2007-12-05
申请号：EP06710543.7
申请日：2006-03-07
申请人： Pfizer, Inc.
发明人： HANAZAWA, Takeshi , HIRANO, Misato , INOUE, Tadashi , NAGAYAMA, Satoshi , NAKAO, Kazunari , SHISHIDO, Yuji , TANAKA, Hirotaka
IPC分类号： C07C311/08 , C07C317/44 , C07C323/62 , C07D213/56 , C07D213/74 , C07D213/76 , A61P29/00 , A61K31/145 , A61K31/44
CPC分类号： C07C61/28 , C07C61/40 , C07C311/08 , C07C317/44 , C07C323/62 , C07C2601/02 , C07D213/26 , C07D213/56 , C07D213/74 , C07D213/76
摘要： This invention provides a compound of the formula (I) or a pharmaceutically acceptable salt or solvate thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compounds.
摘要翻译：本发明提供式（I）的化合物：其中变量A，B，D，E和R 1至R 11如说明书中所定义。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式